JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
